Overview

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks. At week 8 all patients were administered a combination treatment with valsartan 160 mg and fluvastatin 80 mg.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Fluvastatin
Valsartan